2CUREX A/S

Their core work

2CUREX is a Danish biotech SME developing functional precision medicine for cancer patients. Their core technology grows micro-tumors from patient biopsies and tests cancer drugs directly on these living mini-tumors to predict which therapy will actually work for that individual. This bridges a critical gap in oncology: instead of choosing chemotherapy based on genomics or guesswork, clinicians get functional evidence of drug response before treating the patient.

What they specialise in

How they've shifted over time

In 2018-2021, 2CUREX ran as an SME-2 coordinator maturing its own micro-tumor platform toward market — a classic single-product commercialisation push. From 2021 onward they pivoted into the collaborative DECIDER consortium, where their wet-lab functional testing is combined with AI, software engineering and multi-omics data analysis. The trajectory is clear: from standalone device/assay development to embedding their platform inside data-driven, AI-enabled clinical decision systems.

They are moving from a standalone assay provider toward becoming the functional-data layer inside AI-powered oncology decision platforms — attractive for partners building integrated precision medicine offerings.

How they like to work

2CUREX is comfortable in both lead and partner positions: they coordinated their own SME-2 project and then joined a larger research consortium as a specialist contributor. With 15 unique partners across 7 countries in just two projects, their second project is clearly a broad European consortium rather than a small bilateral team. They behave like an SME that uses EU grants strategically — one project to push their own product, another to plug that product into a bigger scientific ecosystem.

Their network spans 15 partners across 7 countries, built almost entirely through the DECIDER consortium. The footprint is firmly European, anchored in Denmark with likely connections to Nordic and Northern European oncology research networks.

What sets them apart

Most precision oncology players sell genomic sequencing or algorithmic risk scores; 2CUREX sells functional evidence — the actual drug response of a patient's own tumor cells. That makes them a rare complement, not a competitor, to genomics-based and AI-based platforms. For a consortium or business partner, they are the group that can convert in-silico predictions into wet-lab confirmation on patient tissue.

Highlights from their portfolio

• MicroCaT
  Their flagship project — coordinated by 2CUREX with EUR 2.99M under SME-2, dedicated entirely to commercialising their Micro-tumor Guided Cancer Therapy Selection technology.
• DECIDER
  A large European research consortium tackling chemotherapy resistance through AI and multi-level data integration, where 2CUREX contributes the functional testing layer.